| Completed | 3 | 433 | Europe, Canada, US, RoW | Aldoxorubicin, INNO-206, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide), Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide | ImmunityBio, Inc. | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | 05/17 | 05/17 | | |
NCT06370871: Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma |
|
|
| Not yet recruiting | 3 | 263 | NA | Brigimadlin, BI 907828, Ezabenlimab, BI 754091, Gemcitabine, Docetaxel | Boehringer Ingelheim | Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS) | 07/26 | 10/28 | | |
2014-000259-99: A comparison of four widely used chemotherapy regimens for the treatment of Ewing sarcoma, a type of bone cancer, to see which is most effective and/or has the fewest side effects. |
|
|
| Ongoing | 2/3 | 400 | Europe | Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Infusion, Capsule, hard, , Cyclophosphamide, HYCAMTIN, CAMPTO, Temodal, GEMZAR, TAXOTERE, Ifosfamide | University of Birmingham, UNIVERSITY OF BIRMINGHAM, European Commission, German Cancer Aid | Recurrent and refractory Ewing sarcoma, Ewing sarcoma, a type of bone cancer, that has either grown during initial treatment or has grown after the end of treatment., Diseases [C] - Cancer [C04] | | | | |
